¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Runyon group III mycobacteria"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® blood group ÇÑ±Û Ç÷¾×Çü
¼³¸í   
  »ç¶÷ÀÇ ÀûÇ÷±¸ Ç¥¸é¿¡´Â ¿©·¯ °¡Áö Ç׿ø¼ºÀ» °¡Áø ¹°ÁúÀÌ Á¸ÀçÇÑ´Ù. Á鿪ÇÐÀû ¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¹°ÁúÀ» Ç¥¸é¿¡ °¡Áö°í ÀÖ´Ù. ±×¸®°í »ç¶÷ÀÇ ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇÒ ¼ö°¡ Àִ Ç×üµµ Á¸ÀçÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº À̰Ϳ¡ µû¶ó ¸î°¡Áö ÇüÀ¸·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ°í, À̰ÍÀ» Ç÷¾×ÇüÀ̶ó°í ÇÑ´Ù. Ç÷¾×ÇüÀº ÀûÇ÷±¸ Ç¥¸é¿¡ Àִ ¾î¶² ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ´À³Ä¿¡ µû¶ó¼­ ¿©·¯ °¡Áö·Î ºÐ·ùµÉ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀΠÇ÷¾×ÇüÀÇ ±¸ºÐ ¹æ¹ý¿¡´Â ABOÇ÷¾×Çü°ú RhÇ÷¾×ÇüÀÌ ÀÖ´Ù.
  
  1. ABO Ç÷¾×Çü
  
  °¡Àå ¸¹ÀÌ »ç¿ëµÇ°í Àִ Ç÷¾×Çü ±¸ºÐ¹ý. ÀûÇ÷±¸ Ç¥¸é¿¡´Â A, BÇüÀÇ µÎ °¡Áö ¹°ÁúÀ» Çϳª, È¤Àº µÑ, ¶Ç´Â Çϳªµµ °¡ÁöÁö ¾ÊÀ» ¼ö°¡ ÀÖ´Ù. ±×¸®°í ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇØ¼­ ÀûÇ÷±¸¸¦ ÆÄ±«Çϰųª ÀÀÁý½Ãų ¼ö Àִ ¹°Áú(Ç×ü)ÀÌ Á¸ÀçÇÑ´Ù. ¹°·Ð ÀÚ½ÅÀÇ ÀûÇ÷±¸°¡ °¡Áö°í Àִ ¹°Áú¿¡ ´ëÇÑ Ç×ü´Â Á¸ÀçÇÏÁö ¾Ê´Â´Ù.
  
  -AÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ AÇ׿ø, Ç÷¾×¼Ó¿¡ B¿¡ ´ëÇÑ Ç×ü
  
  -BÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ BÇ׿ø, Ç÷¾×¼Ó¿¡ A¿¡ ´ëÇÑ Ç×ü
  
  -ABÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø, Ç÷¾×¼Ó¿¡ A,B¿¡ ´ëÇÑ Ç×ü¸¦ °¡ÁöÁö ¾Ê´Â´Ù.
  
  -OÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø ¸ðµÎ¸¦ °¡ÁöÁö ¾Ê°í, Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç׿øÀ» ¸ðµÎ °¡Áø´Ù.
  
  ´ë°³ À̰ÍÀ» ÀÌ¿ëÇÏ¿© ¼öÇ÷ÀǠŸ´ç¼º ¿©ºÎ¸¦ Á¶»çÇÑ´Ù. ¸¸¾à AÇü Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǸ¦ BÇü Ç÷¾×ÇüÀÇ »ç¶÷¿¡°Ô ¼öÇ÷Çϸé BÇü Ç÷¾×ÇüÀ» °¡Áø ÀÚÀÇ ÇǼӿ¡ Àִ A¿¡ ´ëÇÑ Ç×ü¶§¹®¿¡ µé¾î¿Â AÇüÀÇ ÀûÇ÷±¸´Â ÆÄ±«µÇ°Å³ª, ÀÀÁýÀÌ µÈ´Ù. OÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ Ç÷¾×ÀÇ ÀûÇ÷±¸´Â Ç¥¸é¿¡ A, BÀÇ ¾î¶°ÇÑ ¹°Áúµµ °¡Áö°í ÀÖÁö ¾Ê¾Æ¼­ ¾î¶°ÇÑ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô ¼öÇ÷ÇØµµ ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. À̿͠°°Àº ¿ø¸®·Î ABÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷Àº Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç×ü¸¦ ¸ðµÎ °¡Áö°í ÀÖÁö ¾ÊÀ¸¹Ç·Î ¾î¶°ÇÑ Ç÷¾×ÇüÀ̶󵵠¹ÞÀ» ¼ö°¡ ÀÖ´Ù.
  
  2. RhÇ÷¾×Çü
  
  ÀûÇ÷±¸Ç¥¸é¿¡ Àִ D¶ó´Â ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ¿© Ç÷¾×ÇüÀ» ³ª´©´Â ¹æ¹ý. ¸¸¾à D¶ó´Â ¹°ÁúÀÌ ÀûÇ÷±¸ÀǠǥ¸é¿¡ Á¸ÀçÇϸé Rh(+), Á¸ÀçÇÏÁö ¾ÊÀ¸¸é Rh(£­)¶ó°í ÇÑ´Ù. ABOÇ÷¾×Çü¿¡¼­¿Í °°ÀÌ Rh(+)Ç÷¾×ÇüÀ» °¡Áö´Â »ç¶÷ÀÇ ÇǼӿ¡´Â D¶ó´Â ¹°Áú¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÏÁö ¾ÊÁö¸¸ Rh(£­)Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǼӿ¡´Â D¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÑ´Ù. ABOÇ÷¾×Çü°ú ¸¶Âù°¡Áö·Î ¼öÇ÷ÀǠŸ´ç¼ºÀ» °áÁ¤Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • factor III
    Á¦3ÀÎÀÚ
  • mycobacteria
    Ç×»ê±Õ, ¹ÌÄÚ¹ÚÅ׸®¾Æ
  • atomic group
    ¿øÀÚ´Ü
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • amino group
    ¾Æ¹Ì³ë±â
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çüü°è
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atypical mycobacteria Mycobacterium
    ºñÁ¤Çü¹ÌÄÚ¹ÚÅ×·ý
  • group
    ¹«¸®, ±º, Áý´Ü, ¸ðµÒ
  • amino group
    ¾Æ¹Ì³ë±â
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • high risk group
    °íÀ§Ç豺
  • low risk group
    ÀúÀ§Ç豺
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
  • group practice
    Áý´Ü°³¾÷
  • blood group system
    Ç÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mycobacteria
    Ç×»ê±Õ
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â
  • atomic group
    ¿øÀÚ´Ü
  • group antigen
    ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çü±º
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • borderline group
    °æ°è±º
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Runyon classification
    ·¯´Ï¿ÂºÐ·ù
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • DSM-III
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ
  • DSM-III-R
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ °³Á¤ÆÇ
  • Sudan III
    ¼ö´Ü III
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • atypical mycobacteria
    ÀÌÇü<ºñÁ¤Çü>¸¶ÀÌÄÚ¹ÚÅ׸®¾Æ
  • mycobacteria
    Ç×»ê±Õ(ù÷߫ж)
  • mycobacteria, atypical
    ºñÁ¤Çü ¹ÌÄÚ¹ÚÅ×·ý
  • mycobacteria, saprophytic
    ºÎ»ý¼º ¹ÌÄÚ¹ÚÅ×·ý
  • mycobacteria, unclassified
    ¹ÌºÐ·ù ¹ÌÄÚ¹ÚÅ×·ý
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • oculomotor nerve (iii)
    ´«µ¹¸²½Å°æ
  • os metacarpale III ³ª
    ¼Â°¼Õ¹Ù´Ú<Áß¼ö>»À, Á¦»ïÁß¼ö°ñ(ð¯ß²ñéâ¢Íé).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
    [¿¾ ¿ë¾î] ¿¬°ñ¼¼Æ÷±ºÁý
  • Third arch (III)
    ¼Â°±ÁÀÌ
    [¿¾ ¿ë¾î] Á¦»ï±Ã
  • Oculomotor nerve (III)
    ´«µ¹¸²½Å°æ
    [¿¾ ¿ë¾î] µ¿¾È½Å°æ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • end group spine
    ±ê³¡°¡½Ã
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DNA polymerase III
    DNA Æú¸®¸Ó·¹À̽º III
  • enzyme III
    È¿¼Ò(ý£áÈ) III
  • exonuclease III
    ¿¢¼Ò´©Å¬¸®¿¡À̽º III
  • HTLV-III
    (å²) human T cell lymphostrophic virus
  • ribonuclease III
    ¶óÀ̺¸´ºÅ¬¸®¿¡À̽º III
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • acetyl group
    ¾Æ¼¼Æ¿±â(Ðñ)
  • acyl group
    ¾Æ½Ç±â(Ðñ)
  • alcoholic hydroxyl group
    ¾ËÄݼº(àõ) ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • aldehyde group
    ¾Ëµ¥ÇÏÀ̵å±â(Ðñ)
  • amino group
    ¾Æ¹Ì³ë±â(Ðñ)
  • angle methyl group
    ¾Þ±Û¸ÞÆ¿±â(Ðñ)
  • aryl group
    ¾Æ¸±±â(Ðñ)
  • azide group
    ¾ÆÀÚÀ̵å±â(Ðñ)
  • azo group
    ¾ÆÁ¶±â(Ðñ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • control group
    ´ëÁ¶±º
  • group file
    ±×·ì È­ÀÏ
  • high risk group
    °íÀ§Çèµµ±º
  • JPEG [=joint photographic expert group]
    JPEG
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
AT III angiotensin III; antithrombin III
ML I, II, III, IV mucolipidosis I, II, III, IV
NTM Non-Tuberculosis Mycobacteria
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Group III group
A III Angiotensin III
ANG III Angiotensin III
AT III Anti-thrombin III
AP III Antipyrylazo III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • atypical mycobacteria
    ºñÁ¤Çü ¸¶ÀÌÄÚ¹ÚÅ׸®¾Æ
  • Class III
    3±Þ
    µ¿ÀǾî=mesiocclusion. ÇϾǰú ÇÏ¾Ç Ä¡¾Æ°¡ »ó¾Ç¿¡ ºñÇØ Àü¹æ¿¡ À§Ä¡ÇÑ °æ¿ì.
  • class III malocclusion
    Á¦ III±Þ ºÎÁ¤±³ÇÕ
  • laminar III
    Á¦ 3Ãþ
  • lues III
    ¸Åµ¶ 3±â
    1. Èı⠸ŵ¶Àº ¸Å¿ì µå¹°´Ù. 2. ½É¸Æ°ü°è º´º¯ÀÌ 80¡­85%, ÁßÃ߽Űæ°è º´º¯ 5¡­10%, ³ª¸ÓÁö´Â °£À̳ª ´Ù¸¥ ºÎÀ§¿¡ °í¹«Á¾ÀÌ ¹ß»ýÇÑ´Ù.
  • platelet fector III
    Ç÷¼ÒÆÇ Á¦ »ï ÀÎÀÚ
  • pseudo class III
    °¡¼º III ±Þ
  • pseudotumour :

    pseudounipolar bipolar III disorder

    °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III Àå¾Ö, °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III º´
  • transverse facial fracture : µ¿ÀǾî=Le Forte III fracture.

    transverse facial vein

    °¡·Î ¾ó±¼ µ¿¸Æ
  • true class III
    Áø¼º III±Þ ºÎÁ¤ ±³ÇÕ
  • type III
    3Çü
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • allyl group
    ¾Ë¸±±º
  • axon group
    Ãà»è ±º
  • blood group
    Ç÷¾×Çü
    µ¿ÀǾî=blood ty
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
group III mycobacteria Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare.
Synonym: nonchromogens.
(05 Mar 2000)
group II mycobacteria Mycobacteria that produce a yellow pigment even when grown in the dark; when grown in the light, the pigment is orange. These organisms behave as do saprophytes in humans and are nonpathogenic to laboratory animals.
Synonym: scotochromogens.
(05 Mar 2000)
group I mycobacteria Mycobacteria that produce a bright yellow colour when grown in the presence of light. Organisms placed in this group appear to belong to the species Mycobacterium kansasii.
Synonym: photochromogens.
(05 Mar 2000)
group IV mycobacteria Mycobacteria that grow rapidly and that do not produce pigment. Organisms placed in this group belong to such species as Mycobacterium ulcerans and M. Marinum.
(05 Mar 2000)
atypical mycobacteria Species of mycobacteria other than M. Tuberculosis or M. Bovis that can cause disease in immunocompromised humans.
(05 Mar 2000)
mycobacteria <microbiology> Bacteria with unusual cell walls that are resistant to digestion, being waxy, very hydrophobic and rich in lipid, especially esterified mycolic acids. Staining properties differ from those of gram-negative and gram-positive organisms, being acid-fast. Many are intracellular parasites, causing serious diseases such as leprosy and tuberculosis. Cell wall has strong immunostimulating (adjuvant) properties due to muramyl dipeptide (MDP). Mycobacterium bovis causes tuberculosis in cattle, attenuated strain is Bacille Calmette-Guerin (BCG), used for immunisation. Mycobacterium leprae is the causative agent of leprosy. Mycobacterium microti is a mycobacterium that causes tuberculosis like disease in small rodents (Microtus microtus is the vole), will infect mice but not humans and is therefore much used as a laboratory model. Releases large amounts of cAMP which may inhibit lysosome phagosome fusion. Mycobacterium tuberculosis Is an obligate anaerobic nonmotile bacterium, causative agent of tuberculosis in humans. Lives intracellularly in macrophages.
(18 Nov 1997)
angiotensin III <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity.
Chemical name: Angiotensin II, 1-de-L-aspartic acid-
(12 Dec 1998)
annexin III <enzyme> A protein of the annexin family that catalyses the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
Chemical name: 1-D-myo-Inositol-1,2-cyclic-phosphate 2-inositolphosphohydrolase
Registry number: EC 3.1.4.36
(12 Dec 1998)
antithrombin III <haematology> Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream.
Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III.
Conditions that may have an associated low value of antithrombin III include: liver disease and DIC. Normal values are: 0.20 to 0.45 mg/ml or more than 50% of the laboratory control value.
Conditions where there is a deficiency of this important protease inhibitor can result in a condition of hypercoagulation, resulting in an increased risk for blood clot formation.
Inheritance: autosomal dominant.
(13 Jan 1998)
apolipoprotein C-III <biochemistry> An apolipoprotein found in VLDL, HDL, and chylomicrons.
(05 Mar 2000)
arsenazo III <chemical> Metallochrome indicator that changes colour when complexed to the calcium ion under physiological conditions. It is used to measure local calcium ion concentrations in vivo.
Pharmacological action: dyes, indicators and reagents.
Chemical name: 2,7-Naphthalenedisulfonic acid, 3,6-bis((2-arsonophenyl)azo)-4,5-dihydroxy-
(12 Dec 1998)
arteriae intercostales posteriores III-XI posterior intercostal arteries 3-11
band III protein <protein> A 90 kD protein embedded in the surface of the human erythrocyte membrane, identified as the major anion transport/exchange protein. When the red blood cell is in the lungs, brings chlorine ion into the cell in exchange for bicarbonate.
Analogous proteins exist in other erythrocytes. A dimeric transmembrane glycoprotein, with binding sites for many cytolasmic proteins, including ankyrin, on its cytoplasmic domain.
(18 Nov 1997)
palpebra III The semilunar fold formed by the palpebral conjunctiva at the medial angle of the eye, a fold of the conjunctival mucous membrane found in many animals; normally partially hidden in the medial canthus of the eye when at rest, it may be extended to cover part or all of the cornea in a winking-like action to clean the cornea, as in birds.
Synonym: membrana nictitans, nictitating membrane, palpebra III, palpebra tertia, third eyelid.
Synonym: plica lunata, plica semilunaris of eye, semilunar conjunctival fold.
(05 Mar 2000)
ramus collateralis arteriarum intercostalium posteriorum III-XI Branch arising near angle of rib and descending to run along superior border of rib below; distribution: lower half of intercostal spaces 3-11; anastomoses: collateral branches of anterior intercostal arteries.
Synonym: ramus collateralis arteriarum intercostalium posteriorum III-XI.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • age-group
    ¿¬·É Áý´Ü
  • group
    Áý´Ü,¶¼¸¦ Áþ´Ù,ºÐ·ùÇÏ´Ù
  • Group of 77
    77°³±¹ ±×·ì(UNÀÇ ¹«¿ª°³¹ß ȸÀÇ(UNCTAD)ÀÇ È¸¿øÀÎ ¹ßÀü µµ»ó±¹ ±×·ì)
  • Group of Seven
    G;7 ¼±Áø 7°³±¹ ±×·ì
  • blood group
    Ç÷¾×Çü Á¤
  • code group
    ºÎÈ£±º
  • continuous group
    ¿¬¼Ó±º
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • enxounter group
    (Á¤ÀÇ)Áý´Ü °¨¼ö¼º ÈÆ·Ã ±×·ì
  • ethnic group
    (»çȸ)ÀÎÁ¾ Áý´Ü
  • focus group
    Æ÷Ä¿½º ±×·ì(Å×½ºÆ®ÇÒ »óǰ¿¡ ´ëÇØ¼­ ÅäÀÇÇÏ´Â ¼ÒºñÀÚ ±×·ì)
  • fringe group
    ºñÁÖ·ùÆÄ
  • front group
    (À§ÀåÇÑ) Ç¥¸é»óÀÇ Á¶Á÷(´Üü)
  • ginger group
    (Á¤´ç µûÀ§ Á¶Á÷ ³»ºÎÀÇ)Çõ½ÅÆÄ
  • group
    ¹«¸®;ºñÇà ´ë´ë;ºñÇà ¿¬´ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á